Compare Arm Holdings plc (ARM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arm Holdings plc vs Medpace Holdings Inc — how do they compare? Arm Holdings plc trades at $315.81 (market cap $345.41B), while Medpace Holdings Inc trades at $538.23 (market cap $15.37B). The key difference: Arm Holdings plc is far larger — about 22.5× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | MEDP | |
|---|---|---|
Market Cap | $345.41B | $15.37B |
Sector | Technology | Technology |
52-Week High | $439.46 | $620.59 |
52-Week Low | $104.55 | $308.88 |
Enterprise Value | $342.26B | $14.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
MEDP trades at $538.23, up 0.51% with a bullish technical signal and strong fundamentals. The stock shows robust profitability with 17.19% net margins and 77.25% ROE, though valuations appear elevated with a P/E of 33.87. Recent earnings consistently beat expectations, and 2026 projections indicate revenue growth to $2.7B. Technical analysis shows support at $527 and resistance at $543, with the current price near pivot point $535.
MEDP presents growth potential from strong CRO demand and earnings momentum, but faces risks from class action lawsuits and elevated valuation multiples. Analyst consensus is cautious with 74% hold ratings and a $479 price target below current levels. The stock's outlook depends on maintaining backlog quality amid rising cancellations and AI investment delays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
